New patient studies surrounding Retatrutide , specifically the high-dose formulation referred to as ZPHC, indicate a considerable benefit on weight reduction and associated chronic illnesses . Scientists posit that this dual agonist , affecting both GLP-1 and GIP pathways , could represent a noteworthy advance in the treatment of obesity and conne